u/Ad_Weekly · 218d agono track record yet
$IBRX (ImmunityBio) can become the next short-term rocket/long-term investment
ImmunityBio's Anktiva immunotherapy targets IL-15 to boost natural killer cells and has demonstrated clinical efficacy in bladder cancer with FDA approval. Upcoming catalysts include EMA approval, Q4 2025 earnings, and high short interest (38.8%), positioning the stock for both short-term gains from short covering and long-term upside as the company scales production and expands into lung cancer, glioblastoma, HIV, and other indications.
At post $6.93Now $8.14+17.5% since postedas of Sep 15, 4:30 PM ET